Overview
A study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with T2DM.
Description
A multi-center, randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with T2DM.
Eligibility
Inclusion Criteria:
- Participants 18-65 years old, inclusive
- BMI of 25 - 40, inclusive
- Stable body weight for two months
Exclusion Criteria:
- History of significant medical conditions and malignancy
- Uncontrollable hypertension
- History of alcoholism or drug addiction within 1 year prior to Screening
- Current or recent participation in an investigational clinical trial